[
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=656f8a72bb5015e19f0233740f7f9fb3e6a84d169703dd5588d153df056944f9",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761237060,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 137225041,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=656f8a72bb5015e19f0233740f7f9fb3e6a84d169703dd5588d153df056944f9"
    }
  },
  {
    "ts": null,
    "headline": "Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity Studies",
    "summary": "Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity Studies",
    "url": "https://finnhub.io/api/news?id=09663d6e889e48e1ae55bdffdeaa1d70eb2df5b617c49736cecd9a6ede4fc350",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761235953,
      "headline": "Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity Studies",
      "id": 137225006,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity Studies",
      "url": "https://finnhub.io/api/news?id=09663d6e889e48e1ae55bdffdeaa1d70eb2df5b617c49736cecd9a6ede4fc350"
    }
  },
  {
    "ts": null,
    "headline": "Radiopharmaceuticals Market to Reach US$ 13.4 Billion by 2033 | Astute Analytica",
    "summary": "Surging multibillion dollar acquisitions and a pipeline of innovative therapies define the current landscape. A strong focus on oncology theranostics, supported by new regulatory approvals, is rapidly advancing personalized cancer treatment possibilities.Chicago, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The global radiopharmaceuticals market was valued at US$ 6.8 billion in 2024 and is expected to reach US$ 13.4 billion by 2033, growing at a CAGR of 7.8% during the forecast period 2025–2033. The radiop",
    "url": "https://finnhub.io/api/news?id=258ee801c9efed665132d97319bf8eff446230eb17b25f9d8eed1847a91003b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761233400,
      "headline": "Radiopharmaceuticals Market to Reach US$ 13.4 Billion by 2033 | Astute Analytica",
      "id": 137197693,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Surging multibillion dollar acquisitions and a pipeline of innovative therapies define the current landscape. A strong focus on oncology theranostics, supported by new regulatory approvals, is rapidly advancing personalized cancer treatment possibilities.Chicago, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The global radiopharmaceuticals market was valued at US$ 6.8 billion in 2024 and is expected to reach US$ 13.4 billion by 2033, growing at a CAGR of 7.8% during the forecast period 2025–2033. The radiop",
      "url": "https://finnhub.io/api/news?id=258ee801c9efed665132d97319bf8eff446230eb17b25f9d8eed1847a91003b7"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?",
    "summary": "Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.",
    "url": "https://finnhub.io/api/news?id=ae6afbec598fa70842fd7d7bc158de8d879174b55ffb1b2beab79012399c52e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761230340,
      "headline": "Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?",
      "id": 137197694,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.",
      "url": "https://finnhub.io/api/news?id=ae6afbec598fa70842fd7d7bc158de8d879174b55ffb1b2beab79012399c52e7"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?",
    "summary": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=b532268a2a256c944be2981163cc3d39175132f4f71eb4492943717a81d5e38f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761228031,
      "headline": "Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?",
      "id": 137197695,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=b532268a2a256c944be2981163cc3d39175132f4f71eb4492943717a81d5e38f"
    }
  },
  {
    "ts": null,
    "headline": "How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?",
    "summary": "Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded drug headwinds.",
    "url": "https://finnhub.io/api/news?id=4a68aa202d270a85b122ee63dffdc85f1bc0445566e6d8ea2ac60f5fdec87034",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761227700,
      "headline": "How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?",
      "id": 137197696,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded drug headwinds.",
      "url": "https://finnhub.io/api/news?id=4a68aa202d270a85b122ee63dffdc85f1bc0445566e6d8ea2ac60f5fdec87034"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk’s new ‘king’ tightens his grip at obesity drug giant",
    "summary": "A board shake-up at Novo Nordisk has blindsided the market and concentrated power in the hands of one man at the top of one of Europe’s biggest...",
    "url": "https://finnhub.io/api/news?id=83a2e7d0d0c66fbd5af2077bf33c42095eee602ee5d692311c9ee38f7b575a49",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761224410,
      "headline": "Novo Nordisk’s new ‘king’ tightens his grip at obesity drug giant",
      "id": 137197698,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A board shake-up at Novo Nordisk has blindsided the market and concentrated power in the hands of one man at the top of one of Europe’s biggest...",
      "url": "https://finnhub.io/api/news?id=83a2e7d0d0c66fbd5af2077bf33c42095eee602ee5d692311c9ee38f7b575a49"
    }
  },
  {
    "ts": null,
    "headline": "Is Novo Nordisk (NVO) The Best Weight-Loss Stock to Buy?",
    "summary": "We recently published 10 Trending Stocks Moving These Days. Novo Nordisk A/S (NYSE:NVO) is one of the trending stocks moving these days. Karen Finerman, CEO & Co-founder, Metropolitan Capital Advisors, said in a recent program on CNBC that she likes NVO amid the company’s weight-loss drug business. “All this talk about GLP-1s? No, I’m not […]",
    "url": "https://finnhub.io/api/news?id=2d2bee8c0a94f4bd46d366b76a0844860fdaaf1d25112cd57317b4bec19c2dd1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761219620,
      "headline": "Is Novo Nordisk (NVO) The Best Weight-Loss Stock to Buy?",
      "id": 137197699,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 10 Trending Stocks Moving These Days. Novo Nordisk A/S (NYSE:NVO) is one of the trending stocks moving these days. Karen Finerman, CEO & Co-founder, Metropolitan Capital Advisors, said in a recent program on CNBC that she likes NVO amid the company’s weight-loss drug business. “All this talk about GLP-1s? No, I’m not […]",
      "url": "https://finnhub.io/api/news?id=2d2bee8c0a94f4bd46d366b76a0844860fdaaf1d25112cd57317b4bec19c2dd1"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith)",
    "summary": "Discover why Viking Therapeutics, Inc.'s VK2735 could lead GLP-1 obesity drugs. Click for my updated look at VKTX stock following its Q3 earnings release.",
    "url": "https://finnhub.io/api/news?id=81dffc518d7ac525fdbe0d394bcc51a1233cc19364ee4382fca7e75993e60008",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761216162,
      "headline": "Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith)",
      "id": 137196831,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1192090097/image_1192090097.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why Viking Therapeutics, Inc.'s VK2735 could lead GLP-1 obesity drugs. Click for my updated look at VKTX stock following its Q3 earnings release.",
      "url": "https://finnhub.io/api/news?id=81dffc518d7ac525fdbe0d394bcc51a1233cc19364ee4382fca7e75993e60008"
    }
  },
  {
    "ts": null,
    "headline": "Nanobiotix S.A: Behind The Recent Momentum",
    "summary": "Despite potential blockbuster royalties, NBTX's $1.1B stock valuation appears stretched due to limited pipeline and reliance on J&J for development. Read the full analysis here.",
    "url": "https://finnhub.io/api/news?id=0127b2e224e3f5a2e06d17c9ba056b5729805fc2de7402af0ef893528c008f4b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761215085,
      "headline": "Nanobiotix S.A: Behind The Recent Momentum",
      "id": 137196767,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1281832252/image_1281832252.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Despite potential blockbuster royalties, NBTX's $1.1B stock valuation appears stretched due to limited pipeline and reliance on J&J for development. Read the full analysis here.",
      "url": "https://finnhub.io/api/news?id=0127b2e224e3f5a2e06d17c9ba056b5729805fc2de7402af0ef893528c008f4b"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics: The Prime Target In The Obesity Gold Rush",
    "summary": "Viking Therapeutics focuses on metabolic therapies with a strong pipeline, takeover potential, and late-stage obesity drug VK2735. Check out why VKTX stock is a buy.",
    "url": "https://finnhub.io/api/news?id=b9a82a43323d724bd37247a20ed5cf0728ad753ea2ec3a15956818d98315b03a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761213917,
      "headline": "Viking Therapeutics: The Prime Target In The Obesity Gold Rush",
      "id": 137196743,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2241752128/image_2241752128.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Viking Therapeutics focuses on metabolic therapies with a strong pipeline, takeover potential, and late-stage obesity drug VK2735. Check out why VKTX stock is a buy.",
      "url": "https://finnhub.io/api/news?id=b9a82a43323d724bd37247a20ed5cf0728ad753ea2ec3a15956818d98315b03a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Accelerates On Obesity Data While Novo Nordisk Retreats",
    "summary": "Eli Lilly and Company is a Strong Buy due to strong growth in obesity and diabetes drugs and pipeline innovation. Learn more about LLY stock here.",
    "url": "https://finnhub.io/api/news?id=14aa051447df90e04e146312100c5763add4a54a5eca675f197b1be3a7d4bac8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761206448,
      "headline": "Eli Lilly Accelerates On Obesity Data While Novo Nordisk Retreats",
      "id": 137196251,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503208/image_521503208.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Company is a Strong Buy due to strong growth in obesity and diabetes drugs and pipeline innovation. Learn more about LLY stock here.",
      "url": "https://finnhub.io/api/news?id=14aa051447df90e04e146312100c5763add4a54a5eca675f197b1be3a7d4bac8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY): 3 Reasons We Love This Stock",
    "summary": "Since April 2025, Eli Lilly has been in a holding pattern, posting a small loss of 2.2% while floating around $811. The stock also fell short of the S&P 500’s 24.7% gain during that period.",
    "url": "https://finnhub.io/api/news?id=5c0fa8707a30895eeadeb5593be4b62a722fe7687aaea9357bdf8cb9a4af2e05",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761192180,
      "headline": "Eli Lilly (LLY): 3 Reasons We Love This Stock",
      "id": 137197700,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Since April 2025, Eli Lilly has been in a holding pattern, posting a small loss of 2.2% while floating around $811. The stock also fell short of the S&P 500’s 24.7% gain during that period.",
      "url": "https://finnhub.io/api/news?id=5c0fa8707a30895eeadeb5593be4b62a722fe7687aaea9357bdf8cb9a4af2e05"
    }
  },
  {
    "ts": null,
    "headline": "Why is Eli Lilly and Company (LLY) One of the Best Long Term Low Volatility Stocks to Buy Right Now?",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to buy right now. On October 17, J.P. Morgan analyst Chris Schott maintained a bullish stance on Eli Lilly and Company (NYSE:LLY), keeping his Buy rating. The same day, Eli Lilly and Company (NYSE:LLY) announced results from the primary overall […]",
    "url": "https://finnhub.io/api/news?id=94871980dc3913e7bdbace494e129144bcf28af9a66a6c04a07af76adbf80bc6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761186927,
      "headline": "Why is Eli Lilly and Company (LLY) One of the Best Long Term Low Volatility Stocks to Buy Right Now?",
      "id": 137197701,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to buy right now. On October 17, J.P. Morgan analyst Chris Schott maintained a bullish stance on Eli Lilly and Company (NYSE:LLY), keeping his Buy rating. The same day, Eli Lilly and Company (NYSE:LLY) announced results from the primary overall […]",
      "url": "https://finnhub.io/api/news?id=94871980dc3913e7bdbace494e129144bcf28af9a66a6c04a07af76adbf80bc6"
    }
  },
  {
    "ts": null,
    "headline": "Sizing Up Eli Lilly After Obesity and Alzheimer’s Advances and a 7% Price Jump",
    "summary": "Thinking about what to do with Eli Lilly shares? You’re certainly not alone. The stock has been climbing the leaderboard for years, with a staggering 554.4% return over five years and 132.8% gains for anyone holding on since mid-2021. But if you’ve checked your portfolio lately, you might have noticed a few unexpected moves. Over the last month, Lilly edged up 7.6%, even in the face of a minor 1.7% slip for the week. For the year, it’s showing a modest 4.4% climb, but that’s coming off last...",
    "url": "https://finnhub.io/api/news?id=9a3b41757cee1f71ffaed48ab1270caa60154e394c3d353b144e3fb224e2b31a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761185394,
      "headline": "Sizing Up Eli Lilly After Obesity and Alzheimer’s Advances and a 7% Price Jump",
      "id": 137197702,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Thinking about what to do with Eli Lilly shares? You’re certainly not alone. The stock has been climbing the leaderboard for years, with a staggering 554.4% return over five years and 132.8% gains for anyone holding on since mid-2021. But if you’ve checked your portfolio lately, you might have noticed a few unexpected moves. Over the last month, Lilly edged up 7.6%, even in the face of a minor 1.7% slip for the week. For the year, it’s showing a modest 4.4% climb, but that’s coming off last...",
      "url": "https://finnhub.io/api/news?id=9a3b41757cee1f71ffaed48ab1270caa60154e394c3d353b144e3fb224e2b31a"
    }
  }
]